Compare BRCB & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRCB | CHRS |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.2M | 159.1M |
| IPO Year | 2025 | 2014 |
| Metric | BRCB | CHRS |
|---|---|---|
| Price | $10.59 | $0.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $11.71 | $7.75 |
| AVG Volume (30 Days) | 523.4K | ★ 1.6M |
| Earning Date | 11-10-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $200,321,000.00 | N/A |
| Revenue This Year | $27.52 | $34.69 |
| Revenue Next Year | $24.44 | $70.40 |
| P/E Ratio | $138.63 | ★ N/A |
| Revenue Growth | ★ 24.49 | N/A |
| 52 Week Low | $6.11 | $0.73 |
| 52 Week High | $25.20 | $2.62 |
| Indicator | BRCB | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 61.68 | 32.51 |
| Support Level | $6.68 | N/A |
| Resistance Level | $15.72 | $1.53 |
| Average True Range (ATR) | 0.83 | 0.10 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 63.92 | 6.37 |
Black Rock Coffee Bar Inc is an operator of guest-centric, drive-thru coffee bars offering premium caffeinated beverages and an elevated in-store experience crafted by its engaging baristas. The company offers wide variety of coffee from classic espresso-based drinks such as Lattes, Americanos, and Cappuccinos, as well as signature creations like the Caramel Blondie, Mexican Mocha, and Blackout. It offers a variety of savory and sweet items, including breakfast burritos, sausage cheddar sandwiches, banana bread, and glazed donut holes.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.